Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
KRRO Korro Bio	$12.34 +3.4%	$14.50	$10.29 ▼ $98.00	$112.12M	2.45	109,514 shs	76,415 shs
LRMR Larimar Therapeutics	$3.08 -5.2%	$2.39	$1.61 ▼ $11.20	$208.09M	0.79	841,999 shs	1.56 million shs
NKTX Nkarta	$1.73 -2.8%	$1.88	$1.31 ▼ $8.23	$126.30M	0.72	1.05 million shs	1.03 million shs
OCUP Ocuphire Pharma		$1.26	$1.07 ▼ $3.40	$30.33M	0.2	171,840 shs	676,700 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
KRRO Korro Bio	+3.35%	-0.96%	-3.74%	-29.24%	-63.11%
LRMR Larimar Therapeutics	-5.23%	+12.41%	+68.31%	+31.06%	-56.13%
NKTX Nkarta	-2.81%	-4.95%	-0.57%	-13.50%	-71.02%
OCUP Ocuphire Pharma	0.00%	0.00%	0.00%	0.00%	-23.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
KRRO Korro Bio	2.7145 of 5 stars	3.6	3.0	0.0	0.0	3.8	0.0	0.6
LRMR Larimar Therapeutics	2.5329 of 5 stars	3.6	3.0	0.0	0.0	3.0	1.7	0.0
NKTX Nkarta	2.6648 of 5 stars	3.6	3.0	0.0	0.0	2.2	1.7	0.6
OCUP Ocuphire Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
KRRO Korro Bio	3.29	Buy	$102.43	730.05% Upside
LRMR Larimar Therapeutics	3.11	Buy	$18.50	500.65% Upside
NKTX Nkarta	3.13	Buy	$14.33	728.52% Upside
OCUP Ocuphire Pharma	3.00	Buy	$14.00	∞ Upside

Current Analyst Ratings Breakdown

Latest OCUP, NKTX, KRRO, and LRMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/24/2025	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00
6/24/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00
6/10/2025	NKTX Nkarta	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$16.00 ➝ $14.00
5/15/2025	NKTX Nkarta	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/15/2025	NKTX Nkarta	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/13/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/13/2025	KRRO Korro Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$155.00 ➝ $90.00
5/8/2025	KRRO Korro Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$115.00 ➝ $100.00
4/29/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	KRRO Korro Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$74.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
KRRO Korro Bio	$2.27M	51.05	N/A	N/A	$17.12 per share	0.72
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$2.69 per share	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	$5.78 per share	N/A
OCUP Ocuphire Pharma	$16.45M	0.00	N/A	N/A	$2.20 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
KRRO Korro Bio	-$83.58M	-$9.44	N/A	N/A	N/A	N/A	-51.64%	-37.94%	8/12/2025 (Estimated)
LRMR Larimar Therapeutics	-$80.60M	-$1.49	N/A	N/A	N/A	N/A	-52.48%	-46.08%	8/6/2025 (Estimated)
NKTX Nkarta	-$108.79M	-$1.51	N/A	N/A	N/A	N/A	-26.64%	-21.62%	8/12/2025 (Estimated)
OCUP Ocuphire Pharma	-$9.99M	-$0.49	N/A	N/A	N/A	-85.75%	-30.19%	-27.55%	N/A

Latest OCUP, NKTX, KRRO, and LRMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	NKTX Nkarta	-$0.44	-$0.43	+$0.01	-$0.43	N/A	N/A
5/7/2025	Q1 2025	KRRO Korro Bio	-$2.60	-$2.49	+$0.11	-$2.49	$0.13 million	$2.55 million
4/30/2025	Q1 2025	LRMR Larimar Therapeutics	-$0.42	-$0.46	-$0.04	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
NKTX Nkarta	N/A	N/A	N/A	N/A	N/A
OCUP Ocuphire Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
KRRO Korro Bio	N/A	9.41	9.41
LRMR Larimar Therapeutics	N/A	7.48	7.48
NKTX Nkarta	N/A	14.48	14.48
OCUP Ocuphire Pharma	N/A	10.68	10.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
KRRO Korro Bio	13.18%
LRMR Larimar Therapeutics	91.92%
NKTX Nkarta	80.54%
OCUP Ocuphire Pharma	14.97%

Insider Ownership

Company	Insider Ownership
KRRO Korro Bio	4.60%
LRMR Larimar Therapeutics	4.50%
NKTX Nkarta	8.40%
OCUP Ocuphire Pharma	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
KRRO Korro Bio	70	9.39 million	8.96 million	No Data
LRMR Larimar Therapeutics	30	64.03 million	61.15 million	Optionable
NKTX Nkarta	140	70.96 million	65.00 million	Optionable
OCUP Ocuphire Pharma	14	25.92 million	24.47 million	Optionable

OCUP, NKTX, KRRO, and LRMR Headlines

Recent News About These Companies

Drug company founder pulls plug on proxy fight at her former company

April 11, 2025 | crainsdetroit.comC

Night Vision Disturbances Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ocuphire Pharma, Viatris

April 10, 2025 | theglobeandmail.com

Ousted founder of drug development company tries to take back the reins

March 28, 2025 | crainsdetroit.comC

Shareholder group nominates slate of director candidates for Opus Genetics

February 7, 2025 | markets.businessinsider.com

Opus Genetics sets April 30 for 2025 Annual Meeting

January 24, 2025 | msn.com

Opus Genetics reinstated with a Buy at H.C. Wainwright

November 14, 2024 | markets.businessinsider.com

Opus Genetics Announces Financial Results for Third Quarter 2024 and Provides Corporate Update

November 12, 2024 | markets.businessinsider.com

Global Dry Eye Disease Treatment Market Projected to Cross USD 9 Billion by 2030 | DelveInsight

October 31, 2024 | prnewswire.co.ukP

Opus Genetics acquired, becomes public company based in NC

October 31, 2024 | ncbiotech.orgN

Foundation Fighting Blindness: The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics

October 26, 2024 | finanznachrichten.de

Ocuphire Pharma, Inc. Announces Acquisition of Opus Genetics

October 26, 2024 | finanznachrichten.de

The RD Fund Announces Ocuphire Pharma's Acquisition of Opus Genetics

October 25, 2024 | prnewswire.com

Rx Rundown: Opella, Samsung Biologics, Dimension and more

October 25, 2024 | mmm-online.comM

Ocuphire Pharma, Opus Genetics Merge in All-Stock Deal

October 24, 2024 | precisionmedicineonline.comP

Ocuphire Pharma Merges with Opus Genetics, Renamed Opus Genetics

October 24, 2024 | finance.yahoo.com

Ocuphire buys Opus Genetics, grows gene therapy pipeline

October 24, 2024 | thepharmaletter.comT

Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders

October 24, 2024 | standard-journal.comS

Ocuphire and Opus Genetics merge to develop IRD gene therapy

October 24, 2024 | finance.yahoo.com

Ocuphire Pharma price target lowered to $10 from $18 at Canaccord

October 24, 2024 | markets.businessinsider.com

Ocuphire completes acquisition of Opus Genetics

October 22, 2024 | ophthalmologytimes.comO

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUP, NKTX, KRRO, and LRMR Company Descriptions

Korro Bio NASDAQ:KRRO

$12.34 +0.40 (+3.35%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$12.34 0.00 (0.00%)

As of 06/26/2025 04:04 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Larimar Therapeutics NASDAQ:LRMR

$3.08 -0.17 (-5.23%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$3.05 -0.03 (-1.01%)

As of 04:23 AM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Nkarta NASDAQ:NKTX

$1.73 -0.05 (-2.81%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.74 +0.02 (+0.87%)

As of 04:01 AM Eastern

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Ocuphire Pharma NASDAQ:OCUP

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was founded in 2018 and is headquartered in Farmington Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time